Search Results - "Eskazan, A.E"

Carfilzomib in Relapsed/Refractory Multiple Myeloma, Single Center Experience by Aydin, Y, Erdogan, I, Salihoglu, A, Elverdi, T, Yalniz, F.F, Berk, S, Sadri, S, Keskin, D, Eskazan, A.E, Ar, M.C, Ongoren, S, Baslar, Z, Soysal, T

Get full text

IgD Multiple Myeloma, Descriptive Report of Eight Cases, Single Centre Experience by Ongoren, S, Erdogan, I, Salihoglu, A, Elverdi, T, Yalniz, F.F, Berk, S, Sadri, S, Keskin, D, Yurttas, N.O, Eskazan, A.E, Ar, M.C, Baslar, Z, Soysal, T, Aydin, Y

Get full text

PB1904 PROPHYLAXIS FOR OCCULT HBV INFECTION UNDER IBRUTINIB THERAPY: MANDATORY OR OPTIONAL? by Ercaliskan, A., Eskazan, A.E., Salihoglu, A., Keskin, D., Ozmen, D., Elverdi, T., Ar, M.C., Soysal, T.

“…Background: Ibrutinib is a Bruton's tyrosine kinase inhibitor which plays a critical role in the management of some B cell malignancies. Although there are…”
Get full text

PB1929 POTENTIAL DRUG‐DRUG INTERACTIONS AMONG PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDER TYROSINE KINASE INHIBITOR THERAPY WITH IMATINIB by Kunbaz, A., Eskazan, A.E., Ozmen, D., Sasmaz, A., Hakmi, A., Shahab, S., Elverdi, T., Salihoglu, A., Ar, M.C., Soysal, T.

“…Background: The introduction of imatinib (IM) has revolutionized the treatment of chronic myeloid leukemia (CML). CML patients (pts) achieving optimal…”
Get full text